Matthew A Miller1, Douglas N Fish2, Gerard R Barber1, Michelle A Barron3, Tiffany A Goolsby1, Pierre Moine4, Scott W Mueller5. 1. Department of Pharmacy Services, University of Colorado Health-Anschutz Medical Campus, 12401 East 17th Avenue, Aurora, CO, 80045, USA; Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Mail Stop C238, 12850 E. Montview Blvd., Aurora, CO, 80045, USA. 2. Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Mail Stop C238, 12850 E. Montview Blvd., Aurora, CO, 80045, USA. 3. Division of Infectious Diseases, University of Colorado Denver School of Medicine, 12401 East 17th Avenue, Aurora, CO, 80045, USA. 4. Department of Anesthesiology, University of Colorado Denver, School of Medicine, Aurora, CO, 80045, USA. 5. Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Mail Stop C238, 12850 E. Montview Blvd., Aurora, CO, 80045, USA. Electronic address: Scott.Mueller@UCDenver.edu.
Abstract
BACKGROUND: Methicillin-susceptible Staphylococcus aureus (MSSA) is a frequent cause of bloodstream infections (BSI). Treatment with nafcillin (NAF) has been preferred to cefazolin (CFZ). However, comparable outcomes have been found with CFZ with possibly lower risk for side-effects. This study compared safety and effectiveness of NAF versus CFZ for MSSA BSI. METHODS: This single center retrospective study evaluated adults admitted with MSSA BSI who received NAF or CFZ. Patients receiving ≥24 h of antibiotics were included for safety analyses. Patients receiving NAF or CFZ for ≥75% of a 14 day minimum treatment course were assessed for clinical effectiveness. The primary safety outcome was incidence of renal toxicity with multiple secondary safety endpoints. Clinical success was defined as symptom resolution, repeat negative cultures, lack of additional therapy for presumed failure, and lack of recurrence within 30 days. RESULTS: A total of 130 patients receiving NAF (n = 79) or CFZ (n = 51) were included for safety analysis. Of those, 90 met criteria for effectiveness assessment (NAF n = 40, CFZ n = 50). Baseline characteristics were well matched. NAF was associated with a higher incidence of nephrotoxicity compared to CFZ (25% vs. 2%, RR 1.31, 95% CI 1.15-1.5, p < 0.001), allergic reactions (p = 0.01) and a trend for hepatotoxicity (p = 0.08). Clinical success was achieved in 82% NAF and 94% CFZ treated patients (p = 0.1). CONCLUSION: CFZ was associated with less nephrotoxicity and no difference in clinical success compared to NAF for MSSA BSI. A prospective study comparing NAF to CFZ for MSSA BSI should be conducted to elucidate differences in therapies.
BACKGROUND:Methicillin-susceptible Staphylococcus aureus (MSSA) is a frequent cause of bloodstream infections (BSI). Treatment with nafcillin (NAF) has been preferred to cefazolin (CFZ). However, comparable outcomes have been found with CFZ with possibly lower risk for side-effects. This study compared safety and effectiveness of NAF versus CFZ for MSSA BSI. METHODS: This single center retrospective study evaluated adults admitted with MSSA BSI who received NAF or CFZ. Patients receiving ≥24 h of antibiotics were included for safety analyses. Patients receiving NAF or CFZ for ≥75% of a 14 day minimum treatment course were assessed for clinical effectiveness. The primary safety outcome was incidence of renal toxicity with multiple secondary safety endpoints. Clinical success was defined as symptom resolution, repeat negative cultures, lack of additional therapy for presumed failure, and lack of recurrence within 30 days. RESULTS: A total of 130 patients receiving NAF (n = 79) or CFZ (n = 51) were included for safety analysis. Of those, 90 met criteria for effectiveness assessment (NAF n = 40, CFZ n = 50). Baseline characteristics were well matched. NAF was associated with a higher incidence of nephrotoxicity compared to CFZ (25% vs. 2%, RR 1.31, 95% CI 1.15-1.5, p < 0.001), allergic reactions (p = 0.01) and a trend for hepatotoxicity (p = 0.08). Clinical success was achieved in 82% NAF and 94% CFZ treated patients (p = 0.1). CONCLUSION:CFZ was associated with less nephrotoxicity and no difference in clinical success compared to NAF for MSSA BSI. A prospective study comparing NAF to CFZ for MSSA BSI should be conducted to elucidate differences in therapies.
Authors: Cosby A Stone; Jason Trubiano; David T Coleman; Christine R F Rukasin; Elizabeth J Phillips Journal: Allergy Date: 2019-05-26 Impact factor: 13.146
Authors: Kyle C Molina; Taylor Morrisette; Matthew A Miller; Vanthida Huang; Douglas N Fish Journal: Antimicrob Agents Chemother Date: 2020-06-23 Impact factor: 5.191
Authors: B Lefèvre; B Hoen; F Goehringer; W Ngueyon Sime; N Aissa; C Alauzet; E Jeanmaire; S Hénard; L Filippetti; C Selton-Suty; N Agrinier Journal: Eur J Clin Microbiol Infect Dis Date: 2021-08-12 Impact factor: 3.267
Authors: John M Allen; Lolade Bakare; Anthony M Casapao; Ken Klinker; Lindsey M Childs-Kean; Ariel F Pomputius Journal: Infect Dis Ther Date: 2019-08-08
Authors: Morgan A Wambaugh; Steven T Denham; Magali Ayala; Brianna Brammer; Miekan A Stonhill; Jessica Cs Brown Journal: Elife Date: 2020-05-05 Impact factor: 8.140
Authors: Daniele Roberto Giacobbe; Silvia Dettori; Silvia Corcione; Antonio Vena; Chiara Sepulcri; Alberto Enrico Maraolo; Francesco Giuseppe De Rosa; Matteo Bassetti Journal: Infect Drug Resist Date: 2022-04-22 Impact factor: 4.177
Authors: Alison R Novak; Martin Krsak; Tyree H Kiser; Robert T Neumann; Luis Cava Prado; Kyle C Molina; Scott W Mueller Journal: Open Forum Infect Dis Date: 2021-12-25 Impact factor: 3.835